WebFind the latest Enanta Pharmaceuticals, Inc. (ENTA) stock quote, history, news and other vital information to help you with your stock trading and investing. WebPipeline Overview. *Fixed-dose combination contains glecaprevir and AbbVie's NS5A inhibitor, pibrentasvir. Marketed by AbbVie as MAVYRET (U.S.) and MAVIRET (ex-U.S.).
Enanta Pharmaceuticals, Inc.
WebJan 8, 2024 · Investor and Media Contact: Jennifer Viera 617-744-3848 [email protected] Release Summary Enanta Pharmaceuticals to Provide Updates on … WebApr 6, 2024 · Investors. Enanta Pharmaceuticals is a clinical stage biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create … Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-323, its … The Investor Relations website contains information about Enanta … The Investor Relations website contains information about Enanta … painting over interior chipped paint
Filed by the Registrant
WebMay 7, 2024 · Enanta Pharmaceuticals Inc ... Jennifer Viera-- Senior Director Of Investor Relations And Corporate Communications. Jay R. Luly-- President, Chief Executive Officer And Director. WebAug 8, 2024 · Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q3 2024 Earnings Conference Call August 5, 2024 4:30 PM ETCompany Participants. Jennifer Viera - Investor Relations. Dr. Jay Luly - President and CEO ... WebAbout. Enanta is a clinical stage biotechnology company dedicated to creating oral drugs for viral infections. Our story began in 1995 when we grew from humble beginnings to the company we are today — one that collaborated with AbbVie to discover two protease inhibitor compounds that were each developed and commercialized as part of an AbbVie ... painting over light colors